{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T07:46:56Z","timestamp":1751960816845},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:00:00Z","timestamp":1707523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Satisfactory treatment for patients with unresectable advanced lung cancer has not yet been established. We report a case of unresectable advanced lung cancer (stage IIIb: T2aN3M0) treated with a total of 15 doses of dendritic cells pulsed with a Wilms\u2019 tumor 1 and mucin 1 vaccine in combination with erlotinib, a small molecule epidermal growth factor receptor tyrosine kinase inhibitor, for more than 699\u00a0days without recurrence or metastasis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 63-year-old Korean woman was diagnosed with lung adenocarcinoma by pathology and computed tomography. The adenocarcinoma showed an epidermal growth factor receptor (EGFR) mutation, no anaplastic lymphoma kinase expression, and less than 1% expression of programmed death ligand 1. She received erlotinib alone for approximately 1\u00a0month. She then received erlotinib and the dendritic cells pulsed with Wilms\u2019 tumor 1 and mucin 1 vaccine. The diameter of the erythema at the vaccinated sites was 30\u00a0mm at 48\u00a0hours after the first vaccination. Moreover, it was maintained at more than 20\u00a0mm during the periods of vaccination. These results suggested the induction of antitumor immunity by the vaccine. Remarkably, the tumor size decreased significantly to 12\u00a0mm, a 65.7% reduction, after combined therapy with eight doses of the dendritic cells pulsed with Wilms\u2019 tumor 1 and mucin 1 vaccine and erlotinib for 237\u00a0days based on fluorodeoxyglucose uptake by positron emission tomography\/computed tomography and computed tomography. Interestingly, after 321\u00a0days of combination therapy, the clinical findings improved, and no tumor was detected based on computed tomography. Validation of the tumor\u2019s disappearance persisted for at least 587\u00a0days after treatment initiation, without any indication of recurrence or metastasis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Standard anticancer therapy combined with the dendritic cells pulsed with Wilms\u2019 tumor 1 and mucin 1 vaccine may have therapeutic effects for such patients with unresectable lung adenocarcinoma.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-024-04363-z","type":"journal-article","created":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T01:02:13Z","timestamp":1707526933000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma: a case report"],"prefix":"10.1186","volume":"18","author":[{"given":"Takuya","family":"Kosumi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigetaka","family":"Shimodaira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruo","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Koido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,10]]},"reference":[{"key":"4363_CR1","doi-asserted-by":"publisher","first-page":"943","DOI":"10.2147\/CMAR.S187317","volume":"11","author":"T Lu","year":"2019","unstructured":"Lu T, Yang X, Huang Y, Zhao M, Li M, et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res. 2019;11:943\u201353.","journal-title":"Cancer Manag Res"},{"key":"4363_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.620374","volume":"11","author":"D Stevens","year":"2020","unstructured":"Stevens D, Ingels J, Van Lint S, Vandekerckhove B, Vermaelen K. Dendritic cell-based immunotherapy in lung cancer. Front Immunol. 2020;11: 620374.","journal-title":"Front Immunol"},{"key":"4363_CR3","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.3390\/cells12192404","volume":"12","author":"J Abascal","year":"2023","unstructured":"Abascal J, Oh MS, Liclican EL, Dubinett SM, Salehi-Rad R, Liu B. Dendritic cell vaccination in non-small cell lung cancer: remodeling the tumor immune microenvironment. Cells. 2023;12:2404.","journal-title":"Cells"},{"key":"4363_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nature06175","volume":"449","author":"RM Steinman","year":"2007","unstructured":"Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007;449:419\u201326.","journal-title":"Nature"},{"key":"4363_CR5","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.ejca.2012.11.005","volume":"49","author":"H Takahashi","year":"2013","unstructured":"Takahashi H, Okamoto M, Shimodaira S, Tsujitani S, Nagaya M, Ishidao T, et al. Impact of dendritic cell vaccines pulsed with Wilms\u2019 tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers. Eur J Cancer. 2013;49:852\u20139.","journal-title":"Eur J Cancer"},{"key":"4363_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18103\/mra.v10i4.2762","volume":"10","author":"H Sugiyama","year":"2022","unstructured":"Sugiyama H. WT1 cancer vaccine for the treatment and prevention. Arch Med Res. 2022;10:1\u201345.","journal-title":"Arch Med Res"},{"key":"4363_CR7","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","volume":"15","author":"MA Cheevers","year":"2009","unstructured":"Cheevers MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15:5323\u201337.","journal-title":"Clin Cancer Res"},{"key":"4363_CR8","doi-asserted-by":"publisher","first-page":"35666","DOI":"10.18632\/oncotarget.26278","volume":"9","author":"A Saltos","year":"2018","unstructured":"Saltos A, Khalil F, Smith M, Li J, Schell M, Antonia SJ, et al. Clinical associations of mucin 1 in human lung cancer and precancerous lesions. Oncotarget. 2018;9:35666\u201375.","journal-title":"Oncotarget"},{"key":"4363_CR9","doi-asserted-by":"publisher","first-page":"5765","DOI":"10.21873\/anticanres.14593","volume":"40","author":"K Nagai","year":"2020","unstructured":"Nagai K, Adachi T, Harada H, Eguchi S, Sugiyama H, Miyazaki Y. Dendritic cell-based immunotherapy pulsed with Wilms tumor 1 peptide and mucin 1 as an adjuvant therapy for pancreatic ductal adenocarcinoma after curative resection: a phase I\/IIa clinical trial. Anticancer Res. 2020;40:5765\u201376.","journal-title":"Anticancer Res"},{"key":"4363_CR10","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s00262-014-1554-7","volume":"63","author":"M Kobayashi","year":"2014","unstructured":"Kobayashi M, Shimodaira S, Nagai K, Ogasawara M, Takahashi H, Abe H, et al. Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis. Cancer Immunol Immunother. 2014;63:797\u2013806.","journal-title":"Cancer Immunol Immunother"},{"key":"4363_CR11","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1158\/1078-0432.CCR-14-0314","volume":"20","author":"S Koido","year":"2014","unstructured":"Koido S, Homma S, Okamoto M, Takakura K, Mori M, Yoshizaki S, et al. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms\u2019 tumor gene 1 (WT1)-specific MHC class I\/II-restricted epitopes for pancreatic cancer. Clinical Cancer Res. 2014;20:4228\u201339.","journal-title":"Clinical Cancer Res"},{"key":"4363_CR12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.lungcan.2019.02.009","volume":"130","author":"T Jiang","year":"2019","unstructured":"Jiang T, Bai Y, Zhou F, Li W, Gao G, Su C, et al. Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1\/PD-L1 inhibitors. Lung Cancer. 2019;130:76\u201383.","journal-title":"Lung Cancer"},{"key":"4363_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15964","author":"Q Huai","year":"2023","unstructured":"Huai Q, Luo C, Song P, Bie F, Bai G, Li Y, et al. Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non-small cell lung cancer patients with neoadjuvant immunotherapy. Cancer Sci. 2023. https:\/\/doi.org\/10.1111\/cas.15964.","journal-title":"Cancer Sci"},{"key":"4363_CR14","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1007\/s00262-021-03003-5","volume":"70","author":"H Nakajima","year":"2021","unstructured":"Nakajima H, Nakata J, Imafuku K, Hayashibara H, Isokawa K, Udaka K, et al. Identification of mouse helper epitopes for WT1-specific CD4(+) T cells. Cancer Immunol Immunother. 2021;70:3323\u201335.","journal-title":"Cancer Immunol Immunother"},{"key":"4363_CR15","doi-asserted-by":"publisher","first-page":"13415","DOI":"10.1002\/cam4.6052","volume":"12","author":"J Apple","year":"2023","unstructured":"Apple J, Shenolikar R, De Silva K, Sun P, Spira A. Real-world outcomes among patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in the first-line setting. Cancer Med. 2023;12:13415\u201325.","journal-title":"Cancer Med"},{"key":"4363_CR16","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","volume":"12","author":"C Zhou","year":"2011","unstructured":"Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735\u201342.","journal-title":"Lancet Oncol"},{"key":"4363_CR17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239\u201346.","journal-title":"Lancet Oncol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-024-04363-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-024-04363-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-024-04363-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T01:02:49Z","timestamp":1707526969000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-024-04363-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,10]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4363"],"URL":"https:\/\/doi.org\/10.1186\/s13256-024-04363-z","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,10]]},"assertion":[{"value":"20 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the basic principles of the Declaration of Helsinki. After obtaining the opinion of an Accredited Committee for Regenerative Medicine, etc. accredited by the Regional Health and Welfare Bureau (Seiyukai Accredited Committee for Regenerative Medicine, etc., accreditation no. NB5150007), a regenerative medicine provision plan is submitted to the Minister of Health, Labor and Welfare, and the approved plan and facilities providing regenerative medicine (provision plan no. PC 7210019 \u201cDendritic cell vaccine therapy for malignant tumors\u201d).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report and accompanying images. A copy of the consent form is available for review by the Editor-in-Chief of this\u00a0journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None declared.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}